LCTX Lineage Cell Therapeutics Dashboard

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.

Company profile

Ticker

LCTX

Exchange

NYSE

Website

www.biotimeinc.com/

CEO

Brian Culley

Incorporated

California

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Biological Products, (No Diagnostic Substances)

AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Enzon Pharmaceuticals • Denali Therapeutics • Allogene Therapeutics ...

Former names

BIOTIME INC

SEC CIK

0000876343

Corporate docs

Articles of Incorporation & Bylaws

IRS number

943127919

LCTX stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

Lineage Stock Gains After Licensing Pact With Immunomic Therapeutics For Cancer Immunotherapy Platform

20 Apr 21

Lineage Announces Worldwide License Agreement With Immunomic Therapeutics For An Allogeneic Cell-Based Cancer Immunotherapy Based On Its VAC Platform; Co. To Receive $2M Upfront Payment And Up To $67M In Milestones Plus Royalties

20 Apr 21

Lineage to Receive $2 Million Upfront and up to $67 Million in Development and Commercial Milestones Plus Royalties Partnership Leverages the VAC Allogeneic Cancer Immunotherapy Vaccine Platform

Lineage Cell Therapeutics Says OpRegen Data Update To Be Featured At 2021 Association For Research In Vision And Ophthalmology (ARVO) Annual Meeting

12 Apr 21

OpRegen® Data Update to Be Featured at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Christopher D. Riemann, MD Lineage Cell Therapeutics, Inc. (NYSE

Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2021

31 Mar 21

ROCE Insights For Lineage Cell Therapeutics

31 Mar 21

Press releases

Pro users get this 30m faster

Thinking about buying stock in Microvision, Lineage Cell Therapeutics, vTv Therapeutics, electroCore, or Arcadia Biosciences?

20 Apr 21

NEW YORK, April 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MVIS, LCTX, VTVT, ECOR, and RKDA.

Lineage Announces Worldwide License Agreement With Immunomic Therapeutics for an Allogeneic Cell-Based Cancer Immunotherapy Based on Its VAC Platform

20 Apr 21

Lineage to Receive $2 Million Upfront and up to $67 Million in Development and Commercial Milestones Plus Royalties Partnership Leverages the VAC Allogeneic Cancer Immunotherapy Vaccine Platform and Immunomic's

Thinking about buying stock in Arcadia Biosciences, Ocugen, Broadwind, Surface Oncology, or Lineage Cell Therapeutics?

31 Mar 21

NEW YORK, March 31, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RKDA, OCGN, BWEN, SURF, and LCTX.

Lineage Cell Therapeutics Announces Vitelliform Maculopathy Patient Treated With OpRegen® Under Named Patient Compassionate Use

29 Mar 21

Lineage Cell Therapeutics Presents Additional Interim Data on OpRegen® for Dry AMD With Geographic Atrophy

23 Mar 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

11 Mar 21

21 Apr 21

31 Dec 21

Financial summary

Financial statements Chart LCTX financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	32.59M	32.59M	32.59M	32.59M	32.59M	32.59M
Cash burn (monthly)	(positive/no burn)	(positive/no burn)	1.96M	2.4M	1.88M	1.65M
Cash used (since last report)	n/a	n/a	7.26M	8.88M	6.96M	6.09M
Cash remaining	n/a	n/a	25.33M	23.7M	25.62M	26.49M
Runway (months of cash)	n/a	n/a	12.9	9.9	13.6	16.1

Beta Read what these cash burn values mean

Recent insider trades

LCTX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
31 Mar 21	Culley Brian M	Common Shares, no par value	Payment of exercise	Dispose F	No	No	2.35	5,343	12.56K	195,709
31 Mar 21	Culley Brian M	Common Shares, no par value	Option exercise	Aquire M	No	No	2.35	15,450	36.31K	201,052
31 Mar 21	Culley Brian M	RSU Common Shares	Option exercise	Dispose M	No	No	0	15,450	0	77,250
30 Mar 21	Alexandra Hernandez	Common Shares, no par value	Sell	Dispose S	No	No	2.23	6,000	13.38K	0
30 Mar 21	Alexandra Hernandez	Common Shares, no par value	Option exercise	Aquire M	No	No	0.6919	6,000	4.15K	6,000
30 Mar 21	Alexandra Hernandez	Employee Stock Option Common Shares	Option exercise	Dispose M	No	No	0.6919	6,000	4.15K	39,200
15 Mar 21	Culley Brian M	Employee Stock Option Common Shares	Grant	Aquire A	No	No	2.43	1,165,100	2.83M	1,165,100
15 Mar 21	Hogge Gary S.	Employee Stock Option Common Shares	Grant	Aquire A	No	No	2.43	419,500	1.02M	419,500
15 Mar 21	Leavitt Chase C.	Employee Stock Option Common Shares	Grant	Aquire A	No	No	2.43	699,100	1.7M	699,100
15 Mar 21	Alexandra Hernandez	Employee Stock Option Common Shares	Grant	Aquire A	No	No	2.43	42,700	103.76K	42,700

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

LCTX institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

34.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	87	0	NEW
Opened positions	87	0	NEW
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	98.65M	0	NEW
Total shares	55.06M	0	NEW
Total puts	26.5K	0	NEW
Total calls	528.3K	0	NEW
Total put/call ratio	0.1	–	–

Largest owners	Shares	Value	Change
Broadwood Capital	34.01M	$59.85M	NEW
Vanguard	6.21M	$10.93M	NEW
Defender Capital	4.74M	$8.34M	NEW
Prescott General Partners	1.85M	$3.26M	NEW
BLK Blackrock	1.6M	$2.82M	NEW
Geode Capital Management	1.07M	$1.87M	NEW
ExodusPoint Capital Management	807.61K	$1.42M	NEW
Bridgeway Capital Management	680.84K	$1.2M	NEW
Two Sigma Investments	547.22K	$963K	NEW
Two Sigma Advisers	509.87K	$897K	NEW

Largest transactions	Shares	Bought/sold	Change
Broadwood Capital	34.01M	+34.01M	NEW
Vanguard	6.21M	+6.21M	NEW
Defender Capital	4.74M	+4.74M	NEW
Prescott General Partners	1.85M	+1.85M	NEW
BLK Blackrock	1.6M	+1.6M	NEW
Geode Capital Management	1.07M	+1.07M	NEW
ExodusPoint Capital Management	807.61K	+807.61K	NEW
Bridgeway Capital Management	680.84K	+680.84K	NEW
Two Sigma Investments	547.22K	+547.22K	NEW
Two Sigma Advisers	509.87K	+509.87K	NEW

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

International Stem Cell • Astellas Pharma • IVERIC bio • VistaGen Therapeutics • Astellas Pharma • Apellis Pharmaceuticals • Biostage • RPE

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: AAO, Abeona, ACOR, Acorda, adjacent, admitted, advice, advisor, Aeglea, Analyst, Anderson, anesthesiologist, annuity, answer, Aravive, Asia, AstraZeneca, ATM, Atreca, atrophic, attending, attorney, AZN, bailey, banker, Barbara, Bellicum, beneficiary, Bernardino, biochemistry, biographical, biosimilar, Biotie, BITI, Boston, boundary, Brandi, Brisbane, CAA, Calithera, CamberView, career, Carlson, carryover, Celldex, Ceplene, CFA, chair, Chartered, Chase, Chimerix, Citigroup, CMRO, COBRA, Colorado, column, Comarco, concert, continuum, Cornell, corroborated, coupon, Coventry, COVID, Crohn, CTOA, Deborah, delegate, Deputy, Diego, dihydrochloride, diligence, disallowed, discretionary, Doctor, don, Drexel, duly, dying, Edward, effectuated, Elan, exacerbation, Exit, expert, Farrell, Fate, Finland, Floor, footprint, forgivable, forgiven, furlough, Gary, Genocea, Greenbelt, Greenway, Harpoon, headquartered, hearing, histamine, Hogge, honorary, hTERT, hypothesized, Icahn, ICI, Idera, ILS, immunology, Immusol, inevitably, Infinity, inflammatory, Inovio, InterMune, intimate, irreversible, ITMN, Johnson, Lampe, Latham, Leavitt, LLM, loan, logistical, Lynch, magnitude, Magtrol, Mallinckrodt, Marsh, Mast, McLennan, mechanical, Merrill, Mersana, microenvironment, MNK, motion, MSTX, mulroy, natalizumab, nationwide, NBIX, Neon, Neurocrine, NewLink, nominating, nurse, occupy, Odonate, ODT, Orange, Orphagen, outlined, outperformed, paragraph, paused, Paycheck, pecuniary, peer, pension, Pepperdine, PJT, plc, PPP, PPV, predominately, printing, prolonged, QCOR, QIMR, Queensland, Questcor, ratify, Rauth, resignation, resigned, restarted, Revance, RHHBY, risky, Robert, Roche, russell, RVNC, salary, Santa, Savara, SBA, Secretary, setback, shelter, Shire, SHPG, shut, shutdown, signature, simple, Southern, Spero, STAA, STAAR, stipend, Stradling, survey, SVRA, SWCH, Switch, Syndax, Synlogic, Tang, tenure, thereunto, tie, TM, transformed, TSR, Turku, twelfth, TXMD, Tysabri, UCI, UCSD, undersigned, UNITY, unprecedented, unspent, untreated, usability, user, ventilator, wealth, Wharton, Wirth, Yocca, Zeneca, Ziopharm

Removed: advertisement, aesthetic, analyzing, Ascendance, assay, assumption, attestation, attribution, avoiding, background, bankruptcy, biocompatibility, biopsy, brown, Bulletin, caption, chemistry, Coast, collectability, confirmatory, Conversely, core, COSO, deconsolidation, distributed, DNA, doubtful, earliest, endpoint, exclusively, expensing, expired, expiry, feeling, flat, forfeiture, Francisco, gelatin, generating, heart, HIV, hyaluronate, IIB, immaterial, impacting, imposing, induced, inInternal, input, internally, ISO, iTR, lab, lapse, LifeMap, lowering, mimic, muscle, obtainable, offshore, opening, orin, otherin, plasma, PMA, Premvia, prepare, principle, prosecuting, prospective, PureStem®progenitor, ratification, reacquisition, remeasured, renew, repatriation, repealing, SAB, Selection, sodium, specification, straight, sublicense, sublicensed, sublicensee, supplier, telomere, tendon, territorial, Teva, thereon, thiol, unadjusted, unaffiliated, underStaff, underwritten, unilaterally, unique, unqualified, utilizing, vascular, veterinary, waive

From filing 10-K 2020 FY